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Simvastatin Does Not Sensitize IBC3 Her2+ Inflammatory Breast Cancer Brain Metastases 
to Whole Brain Irradiation in an Immunocompromised Mouse Model 
Swaminathan Kumar, B.Tech.*, Advisory Professor: Wendy A. Woodward, M.D., Ph.D. 
 
Retrospective data analysis suggests that inflammatory breast cancer (IBC) 
patients who take statins have better locoregional control after radiotherapy than those 
who do not [23]. Our lab has previously demonstrated that simvastatin radiosensitizes 
IBC cells in vitro [23], and brain metastases have strong expression of cholesterol-
regulation genes compared to lung metastases in vivo [unpublished]. Delaying whole-
brain irradiation (WBI) beyond 21 days is insufficient to reduce the incidence of brain 
metastases (developed by injecting IBC3 cells through the tail vein) in our mouse model 
because even high rates of cell killing leave substantial cell volume in established 
metastases [unpublished].  
With the above data, I hypothesized that the combination of simvastatin and 
whole-brain radiation will reduce the incidence of established brain metastases in vivo.  
I performed two in vivo experiments—in the first, a single-fraction, 10-Gy WBI 
dose was used, and in the second experiment, a 9-Gy WBI dose was given in 3 fractions 
of 3 Gy each. The simvastatin dose was kept constant and was mixed with drinking water 
in both experiments. Brain metastatic lesions were quantified by stereo-microscopy. 
Brains were cryo-sectioned into mirror sections for mass spectrometry-based tissue 
imaging and H&E staining. There was a significant reduction (P < 0.05) in brain metastatic 
burden in the group treated with 10 Gy WBI alone compared to no treatment. Simvastatin 
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by itself did not significantly reduce the brain metastatic burden compared to no 
treatment. There was no significant reduction in brain metastatic burden in the 
combination group compared to the no-treatment or radiation-alone group. There was 
no significant difference in the incidence of brain metastasis between any of the four 
treatment groups. Repeating the experiment with a 9 Gy–dose of WBI given in 3 fractions 
of 3 Gy each also demonstrated no synergy between simvastatin and radiation in this 
model.  
Mass spectrometry-based tissue imaging revealed that treatment with 10 Gy 
radiation (both as a single-agent and in combination with statins) increased cholesterol 
(based on its m/z value of 369.35) levels compared to the no-treatment or simvastatin-
alone group. Mice brain treated with simvastatin alone had low cholesterol levels 
compared to the no-treatment group, confirming the role of statins in inhibiting 
cholesterol biosynthesis. Contrary to my hypothesis, the metastatic burden did not 
correlate with cholesterol levels in the brain parenchyma for any of the treatment groups.  
Thus, simvastatin failed to radiosensitize brain metastases in our model, 
consistent with our published mathematical model [35] and a recently published clinical 
trial [28].   
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Chapter 1: Introduction 
1.1 Breast Cancer 
 Breast cancer is the most prevalent cancer type among American women and is 
the second most common cause of cancer-related death in this population. In 2018, it is 
estimated that there will be 266,120 newly diagnosed cases of breast cancer, and 40,920 
breast cancer-related deaths (1). There are different classifications of breast cancer. 
Clinically, breast cancer is commonly categorized based on the expression of estrogen 
receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 
2 (HER2) (2). Tumors are typically classified as hormone receptor positive (defined as 
positive for ER and or PR), HER2+ (regardless of ER and PR expression), or triple-negative 
(TN), which express neither ER, PR, nor HER2 (37). Molecular classifications of breast 
cancer based on intrinsic gene expression signatures have also been developed, but these 
are not in routine clinical use (2, 45). HER2+ and TN breast cancers are associated with 
higher risks of local and regional recurrence and distant metastasis compared to hormone 
receptor positive breast cancers. 
1.2 Inflammatory Breast Cancer 
Inflammatory breast cancer (IBC) is a clinically-diagnosed subtype of breast cancer 
that accounts for 1-4% of all breast cancers. While non-inflammatory breast cancers often 
present with a palpable mass or are detected by screening mammography, IBC typically 
appears as a red and swollen breast with changes in the overlying skin (commonly called 
“peau d’orange”), with or without a palpable mass (3). IBC is the most lethal form of 
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breast cancer; indeed, approximately 30% of patients with IBC have metastatic disease at 
the time of diagnosis. IBC is commonly HER2+ or TN, though hormone receptor positive 
IBC is not rare.  
1.3 Treatment Options for Breast Cancer  
The approach to treating breast cancer usually involves surgery, radiation therapy 
and systemic therapies. Surgical options include segmental mastectomy (“lumpectomy”) 
in which the tumor and a small margin of normal breast tissue are removed, or 
mastectomy, which entails completely removing the breast. Radiation therapy is typically 
administered as external beam radiation therapy to the whole breast or chest wall. 
Systemic therapy may include chemotherapy, hormonal and/or targeted therapy, 
depending on stage and tumor subtype. The sequencing of surgery, radiation therapy, 
and systemic therapy largely depends on the clinical stage at diagnosis. For patients with 
early-stage breast cancer, surgery is typically performed first so that the cancer can be 
pathologically staged. For early-stage patients who opt for lumpectomy, adjuvant (after 
surgery) radiation therapy is indicated. Radiation therapy is rarely required for early-stage 
patients who elect mastectomy. For patients with more advanced disease at diagnosis, 
including those who are found to have involved lymph nodes, neoadjuvant (before 
surgery) systemic therapy is usually given to reduce disease burden and hopefully 
eliminate micrometastatic disease that may already exist. Following systemic therapy, 
patients then go to surgery followed by adjuvant radiation therapy.  
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Systemic therapies may affect the entire body and can be given either orally or 
intravenously to a patient. Neoadjuvant systemic therapy is used to shrink tumors so that 
surgery is a more feasible option, and may allow patients who would have required 
mastectomy to undergo lumpectomy instead. Neoadjuvant systemic therapy also allows 
oncologists to determine the response of the primary tumor to treatment. Patients who 
have a favorable response to neoadjuvant systemic therapy are known to have an 
improved prognosis compared to patients who have a poor response or progress on 
treatment (46, 47). In patients who receive surgery upfront, adjuvant systemic therapy 
can be used to eliminate residual cancer cells that remain at the primary site or may have 
migrated to a distant part of the body.  
Chemotherapy describes a group of cytotoxic systemic therapies that are used to 
treat breast cancer. The underlying mechanism behind most chemotherapy agents is to 
kill cancer cells that are rapidly dividing; however, this approach can also be lethal to 
normal cells which undergo rapid cell division. These drugs can be classified as one of the 
following: alkylating agents, anti-metabolites, anti-microtubule agents, topoisomerase 
inhibitors, and anthracyclines. The most common chemotherapeutic backbone in breast 
cancer treatment involves use of doxorubicin (an anthracycline), cyclophosphamide (an 
alkylating agent), and paclitaxel (a microtubule poison).  
Targeted therapies are routinely used for the treatment of HER2+ and hormone 
receptor positive breast cancers. Agents like the anti-HER2 monoclonal antibodies 
trastuzumab and pertuzumab, and the HER2 small molecule antagonist lapatinib have 
revolutionized the treatment of both early-stage and advanced HER2+ breast cancer and 
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have markedly improved outcomes for these patients. Similarly, therapies targeting 
estrogen production and/or the estrogen receptor (e.g., selective estrogen receptor 
modulators (SERMs) like tamoxifen, aromatase inhibitors like exemestane, and 
gonadotropin releasing hormone agonists like goserelin or leuprolide) are useful in the 
treatment of hormone receptor positive disease. Although multimodal therapies have 
improved treatment outcomes and cure rates for breast cancer patients with early-stage 
disease, the development of metastatic disease remains the major driver of breast cancer 
related mortality. Novel approaches to treat metastatic disease are still needed. 
1.4 Metastatic disease  
Cancer cells that invade distant organs from the primary tumor site are part of a 
process called metastasis. It is this process that is responsible for most cancer deaths even 
though there have been improvements in detection, tumor removal and treatment. 
Metastatic disease is generally resistant to conventional methods of treatment (4). 
Clinically, metastasis is a major hurdle to achieving significantly better patient outcomes, 
thus making new and improved therapies for treating it an important part of cancer 
research.  
Metastases arise from a set of unique cells which reside within the primary tumor 
(38). The metastatic process is complex, and the tumor cells that form metastases are 
heterogenous clones with different mutations. Only a small percentage of tumor cells that 
are circulating in the bloodstream or migrate to regional lymph nodes will actually 
develop into metastatic lesions (5, 39).  
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Metastasis is a multi-step process, and there remains some controversy regarding 
the mechanisms of several steps. In one model, metastasis begins with a cell undergoing 
a process called the epithelial-mesenchymal transition (EMT) in which it loses adhesion 
with its neighbors (characterized by loss of E-Cadherin expression), invades through the 
basement membrane, migrates to a blood or lymphatic vessel, and then enters the 
systemic circulation (intravasation). EMT is a critical component of this model (48). 
Another model proposes a process called collective migration, whereby small aggregates 
of cells collectively invade and migrate together, resulting in polyclonal metastases (49). 
It is possible that both of these mechanisms contribute to the development of 
inflammatory breast cancer metastases.  
Cancer cells can reach the systemic circulation through the hematogenous route 
(involving blood vessels) or can enter into the lymphatic vessels (lymphatic circulation) 
and reach a nearby lymph node and drain into the blood vessels. Once the tumor cells 
have reached the systemic circulation, they can circulate throughout the body. Cancer 
cells can enter the tissue of a nearby or distant organ, which is referred to as 
extravasation. In order to migrate inside the tissue of the secondary site, the cells could 
move between two endothelial cells or pass through one. Once the tumor cells have 
established themselves within the tissue of the organ, they can begin to develop their 
own network of blood vessels.  
The formation of metastases depends upon the interactions between tumor cells 
and the surrounding tissue of the secondary organ. The majority of the micro-metastases 
that form will not grow into lesions that are detectable in the clinical setting (40). Micro-
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metastases can be widely distributed throughout the tissues of the organ, so it is very 
important to try and eliminate them before they become too large, which is detrimental 
to the structure and function of the secondary organ (40). Eradication of micrometastases 
is one of the major rationales for the use of neoadjuvant systemic therapy. For a disease 
like IBC, where the risk of occult metastatic disease is exceedingly high, early introduction 
of therapy to eradicate these micrometastases likely modifies the course of the disease. 
Radiation therapy is also used to eradicate micrometastatic disease. Examples include the 
use of nodal irradiation to clinically-uninvolved lymph node basins, which has been shown 
to reduce the risk of distant metastasis in breast cancer (50, 51), and even prophylactic 
cranial irradiation (PCI) in small cell lung cancer (SCLC), which has been shown to reduce 
the incidence of brain metastasis and improve survival (52, 53). 
1.5 Brain Metastasis  
Most malignant brain tumors are the result of metastases to the central nervous 
system (41). Lung cancer (40-50%), breast cancer (15-25%), and melanoma (5-20%) are 
the top three sources of brain metastasis (6). While brain metastases can develop at any 
point during the course of disease, metastatic brain lesions typically appear at a later 
point in time after the cancer has spread to other organs (6).  
During the process of brain metastasis, tumor cells may proliferate within the 
brain capillaries before extravasating into the brain tissue. Endothelial cells lining the 
brain vasculature may aid the growth and extravasation of tumor cells (7). The blood-
brain barrier (BBB), which acts as a barrier between the peripheral blood and the fluid in 
the brain, may help the tumor cells enter into the brain parenchyma when it is breached. 
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It is possible that the cancer cells could exit the blood vessel, cross over into the brain 
tissue and then proceed to die or become dormant. Once cells are in the brain tissue, they 
will encounter both microglia and astrocytes, which can be conducive to tumor growth 
and treatment resistance (42-44). 
1.6 Breast Cancer Brain Metastasis  
As mentioned previously, brain metastases can be formed from breast tumors. 
When considering all breast cancer patients, only about 5% will develop brain metastases. 
However, the risk increases greatly for patients with advanced disease at presentation, 
and even more so for patients who already have extracranial metastatic disease. 
Approximately 25-35% of stage IV (metastatic) HER2+ patients and 40-45% of stage IV TN 
patients have or will develop brain metastases (9, 10). It has been reported that 
overexpression of the HER2 protein in a breast cancer cell line that is preferential to the 
brain increased the quantity of large brain lesions significantly, but it did not increase the 
number of micro-lesions (11). HER2 may play a role in establishing the population of brain 
metastasis, but it does not affect the initial stages of brain metastasis (8). These data 
suggest that HER2 is an important driver of increase in brain metastatic burden (larger 
lesions) and does not increase the incidence or the number of brain metastatic lesions.  
Brain metastasis in breast cancer is generally a terminal event, and expected 
survival time is very low (~1 year) for patients who have developed brain metastases. 
Strategies to improve outcomes for breast cancer patients with brain metastases are a 
tremendous unmet need. 
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1.7 IBC Brain Metastasis mouse model 
Animal models are very important for understanding the biology of brain 
metastases and for creating new therapies aimed at treating or preventing this 
phenomenon. One group found that a triple-negative breast cancer cell line only reaches 
the brains of mice approximately 42% of the time (12). To better understand mechanisms 
of brain metastasis in IBC, our group has developed a model using a HER2+ inflammatory 
breast cancer cell line known as IBC3 that goes to the brain approximately two-thirds of 
the time following tail vein injection into immunocompromised SCID-beige mice (13). We 
have developed GFP-labeled IBC3 cells that allow us to quantify the number and burden 
of tumor cells in the brain using fluorescence based stereo microscopy. The veracity of 
this model was confirmed when the genetic knockdown of a brain metastatic specific 
microRNA (miR-141) resulted in a nearly complete absence of brain metastatic lesions. 
Since the IBC3 cell line has a high propensity for forming brain metastases using our tail 
vein injection model, it was used for in vivo experiments discussed in chapter 2. This 
model could be used to mechanistically study IBC brain metastases and to evaluate new 
treatment approaches for IBC brain metastasis. 
1.8 Treatment Strategies for Breast Cancer Brain Metastasis  
 To date, there are generally no curative treatment options for breast cancer 
metastasis to the brain. Palliative treatment options depend on the patient’s burden of 
extracranial disease, response to prior therapies, the possibility of surgery, the quantity, 
location, and size of the lesions, as well as the patient’s expected prognosis. Depending 
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on these factors, patients may undergo surgical resection, whole-brain radiation therapy 
(WBRT), stereotactic radiosurgery (SRS), or intrathecal chemotherapy or targeted 
therapy. WBRT involves giving several low doses of radiation to the entire brain, whereas 
SRS employs high-dose focal irradiation in one or a few fractions. In the U.S., currently 
there are no FDA (Food & Drug Administration) approved systemic or intrathecal 
therapies specifically for brain metastasis arising from breast cancer, however, several 
agents are used off-label and there are ongoing clinical trials (14).  
Surgical resection, WBRT, SRS, and intrathecal therapies are palliative options and 
rarely result in permanent control of disease within the central nervous system (CNS). For 
patients who have good control of extracranial metastases, progression of CNS metastatic 
disease is a major driver of morbidity and mortality. There are no solid guidelines for 
treating patients with recurrent brain lesions. The National Comprehensive Cancer 
Network (NCCN) recommends that patients with stable systemic disease receive surgery, 
re-irradiation or chemotherapy for their brain metastasis. If a patient’s systemic disease 
has progressed, then treatment options might include best supportive care or re-
irradiation (14). As is the case for treatment-naïve brain metastases, strategies to control 
recurrent or progressive brain metastases are needed. 
 Chemotherapy options for patients with brain metastases are somewhat limited 
for several reasons. First of all, patients usually undergo several rounds of chemotherapy 
before they present with brain metastasis which could be chemoresistant. Secondly, 
clinical trials may not include patients with brain metastases (15). CNS penetration of 
many systemic agents is poor, due to the presence of the blood brain barrier (BBB), 
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composed of tight junctions connecting the endothelial cells. There are many active 
transporters inside the cells which pump all but small lipophilic substances back into the 
peripheral circulation (16). When a lesion is approximately 1-2 millimeters in diameter, 
the BBB is compromised and becomes leaky (17). Even though the BBB is compromised 
and chemotherapeutic agents enter the brain, there is usually not enough drug near the 
lesion to make a difference in most cases.  
Trastuzumab is a systemic agent used to treat HER2+ breast cancer. Trastuzumab 
dramatically reduces the incidence and progression of extracranial metastatic disease, 
but since it does not effectively cross the BBB, the CNS is a sanctuary site for HER2+ breast 
cancer metastases. Accordingly, HER2+ brain metastases may become apparent years 
after the primary cancer is cured. Strategies to eradicate micro-metastatic breast cancer 
cells in the CNS that are anatomically shielded from trastuzumab and other systemic 
therapies may improve outcomes for breast cancer patients. The use of prophylactic 
cranial irradiation (PCI) in SCLC is an example of this approach (18).  
PCI is a preventative strategy that employs whole-brain irradiation in patients who 
are at risk for developing brain metastases. There is an elevated risk for brain metastases 
in some advanced primary tumors such as breast cancer, acute lymphoblastic leukemia 
and small-cell lung cancer (54). Even though new therapies are being utilized, patients 
with brain metastases may not survive more than a year after the brain metastases have 
been detected. Undetected brain micro-metastases can be problematic for cancer 
patients. These undetected brain lesions could be an opportunity for employing 
treatments that could alter the environment of the brain so that there can be a reduction 
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or hindrance to brain metastasis formation. This prophylactic approach may even help to 
reduce the cognitive problems that patients’ sometimes experience with conventional 
brain metastasis treatments. While WBRT is commonly used in the treatment of patients 
with clinically evident brain metastases from any solid tumor, or in leukemia patients with 
CNS involvement, to date, prophylactic irradiation of the whole brain is only formally 
recommended for patients diagnosed with limited-stage small cell lung cancer (LS-SCLC) 
(NCCN guidelines).  
Currently, there are no large-scale studies to help evaluate the effectiveness of 
prophylactic cranial irradiation in breast cancer patients. Since PCI has not been used as 
a standard of care for breast cancer patients who are at high risk for brain metastasis, 
inevitably, many of these individuals develop brain metastasis during the course of their 
disease. In order to develop a treatment that effectively reduces the incidence of brain 
metastasis in IBC with a favorable toxicity profile, we must be able to correctly identify 
the patients who are high risk of developing brain metastasis, understand the temporal 
patterns of brain metastasis seeding, and optimize the radiation dose to effectively 
eradicate tumor cells but maximize preservation of the normal brain.  
One strategy to improve the therapeutic index for whole brain irradiation is to 
utilize a radiosensitizer that will preferentially increase the efficacy of radiation therapy 
in tumor cells while not amplifying the adverse effects of radiation therapy in normal 
brain tissue. Based on previous studies in our laboratory linking cholesterol metabolism 
with radiosensitivity in IBC, my thesis project looked at whether we can use 
hydroxymethylglutaryl-CoA (HMC-CoA) reductase inhibitors (“statins”), which inhibit 
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cholesterol biosynthesis, for treating late-stage inflammatory breast cancer brain 
metastasis using our IBC3 model system. 
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Chapter 2: Simvastatin Does Not Sensitize IBC3 Her2+ Inflammatory Breast Cancer Brain 
Metastases to Whole Brain Irradiation in an Immunocompromised Mouse Model 
2.1 Background:  
 Women in western countries have a greater chance of developing breast cancer 
than women in other countries.  Diets in the United States and other western countries 
are typically high in cholesterol and fat, and studies have shown that there is a link 
between obesity and breast cancer. It has also been shown that one of the risk factors for 
breast cancer is high cholesterol levels in the blood (19). Statins are drugs which reduce 
blood cholesterol levels by targeting a key enzyme in the cholesterol biosynthesis 
pathway, HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase. Specifically, statins 
reduce mevalonate levels in cells by inhibiting the HMG-CoA reductase involved in the 
conversion of HMG-CoA to mevalonate. Mevalonate is an intermediate molecule 
converted into cholesterol by multiple enzymes in the cholesterol biosynthesis pathway. 
The effects of statin on breast cancer progression and on breast cancer patients 
diagnosed with high cholesterol levels have been studied. Statins have been shown to 
reduce breast cancer occurrence and improve outcomes.  
2.1.1 Studies from other groups which helped us to form our hypothesis: 
In a ten-year study conducted by researchers in Denmark, patients who used 
simvastatin had far fewer recurrences than patients who did not use the drug (20). 
Another study looked at cholesterol metabolism differences between non-inflammatory 
and inflammatory breast cancer cells. The study found that both non-IBC and IBC cells 
have a higher cholesterol content compared to normal mammary epithelial cells. In 
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cholesterol-depleted microenvironments in vitro, IBC cells could also produce their own 
cholesterol whereas non-IBC cells could not (21). Studies from other groups have shown 
that glioblastoma (GBM) cells are dependent on astrocytes in the brain for cholesterol 
and targeting this metabolic dependency of GBM cells can have therapeutic effects (22).  
2.1.2 Studies from our group which helped me to form my hypothesis:  
From a retrospective patient data analysis, it was found that patients taking statins 
had better primary tumor control after radiotherapy compared to those who did not (23). 
Our lab has previously demonstrated that statins influence inflammatory breast cancer 
(IBC) cells and the tumor microenvironment. First, we found that simvastatin 
radiosensitizes IBC cells in vitro to gamma radiation, likely by targeting stem-like and 
progenitor cells (23). Second, our lab has shown that statins and lipoproteins impact the 
supporting stromal cells, namely mesenchymal stem cells and macrophages, further 
influencing radioresistance in IBC (24). Third, our lab has found using gene expression 
microarrays that IBC brain metastases have strong expression of cholesterol regulation 
genes compared to lung metastases using [unpublished]. Fourth, our lab has shown that 
statins are able to inhibit IBC metastasis formation by upregulating a tumor suppressor, 
FOXO3a (25). Fifth, our lab has found that delaying whole-brain radiotherapy (4 Gy) 
beyond 21 days is insufficient by itself to reduce the incidence of IBC brain metastases 
using a tail-vein injection mouse model (discussed in Section 1.7), because even high rates 
of cell killing leave substantial cell volume in established metastases [unpublished]. Since 
WBI by itself was not sufficient to reduce the incidence of established brain metastasis, 
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my project sought to combine a radiosensitizer with WBI to treat established brain 
metastases.  
2.2 Hypothesis & Specific Aims:  
Based on ours and other groups’ findings, we hypothesized that the combination 
of simvastatin and whole-brain radiation therapy (WBRT) would eradicate established 
brain metastases in vivo, implying a synergy between the intrinsic cancer-cell killing and 
suppression of pro-tumor brain parenchyma.  
To test the above hypothesis, I had three specific aims:  
Specific Aim 1: To optimize the whole brain radiation dose in SCID-beige mice brain 
metastasis model  
Specific Aim 2: To test the combinatorial effects of simvastatin and optimized whole-
brain radiation dose in an IBC brain metastasis mouse model  
Specific Aim 3: To adapt mass spectrometry–based tissue imaging (MSI) methodology to 
understand the cholesterol distribution and its perturbations by simvastatin in brain 
metastatic lesions and the brain tumor microenvironment  
Specific Aim 1 and 2 is discussed in this chapter. Specific Aim 3 will be discussed in 
Chapter 3.  
 
 
 
26 
 
2.3 Materials and Methods: 
(*- Swaminathan Kumar, **- Richard Larson, ***- Shane Stecklein) 
A. Cell line and culture conditions  
For the in vivo studies we used GFP-labeled MDA-IBC3, a HER2+ inflammatory 
breast cancer patient-derived cell line generated in our lab and used previously (13). 
MDA-IBC3 cells were grown in Ham’s –F12 media with 10% fetal bovine serum (FBS), 1% 
antibiotic-antimycotic cocktail, 5 μg/mL insulin and 1 μg/mL hydrocortisone. Cells were 
maintained at 37°C with 5% CO2 and 95% O2 (S.K.). Cells were checked for mycoplasma 
contamination using Lonza’s MycoAlert™ Mycoplasma Detection Kit before using them 
for any experiments (S.K.). Whenever contaminated with mycoplasma, they were treated 
with plasmocin (S.K.). Only mycoplasma-free cells were used for in vitro and in vivo 
experiments (S.K.). Media was changed once every three days for IBC3 cells (S.K.). IBC3 
cells have a doubling time of 76 hours. When they were 70% confluent, they were 
passaged at a 1:4 ratio once every week before injection into the mice (S.K.).  
B. Mouse strain used: 
Three-week-old SCID/Beige mice were purchased from Harlan, USA and housed 
according to institutional guidelines of the University of Texas MD Anderson Cancer 
Center under the Institutional Animal Care and Use Committee approved protocol 
(00001063-RN00). Mice were monitored regularly and were weighed weekly after tumor-
cell injection (S.K., R.L.).  
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C. Intravenous Tail Vein Injection  
IBC3 cells were grown to 60-70% confluency and were tryspinized using 0.25% 
trypsin-EDTA and neutralized with Fetal Bovine Serum (FBS) present in the culture media 
(S.K.). Cells were washed twice with PBS before counting and were counted twice using 
two cell counters, Nexcelom Bioscience’s Cellometer™ Auto T4 Bright Field Cell Counter 
and Bio-Rad’s TC20™ Automated Cell Counter (S.K., R.L.). The average of cell counts from 
the two cell counters were taken as the number of cells present in 1 mL of the cell 
suspension (stock concentration) (S.K.). Stock concentration was adjusted to 2.5 x 106 
cells/mL using PBS and added to 1.5 mL sterile Eppendorf tubes after mixing the cell 
suspension (S.K.). Cells were placed on ice before injection into SCID/Beige mice. 200 μL 
of cell suspension (500000 cells) were injected through the tail vein of 6-week-old mice 
using a 30-gauge needle. Cell injections were done by a veterinary medicine technologist 
at the North Campus Animal Facility of MD Anderson Cancer Center.  
We chose 500000 IBC3 cells because we knew from previous experiments in our 
lab that 500000 cells form brain metastases in 9 weeks in the maximum number of mice 
(70 – 100%) (13). One previous lab member had done serial dilutions of IBC3 cells (500000, 
250000, 50000, 5000, and 500) and injected 10 mice in the tail vein, each with a particular 
number of cells. In a 9-week period without any therapeutic intervention, the groups 
injected with 500000, 250000, 50000, 5000, and 500 cells formed brain metastases at 
incidence rates of 10/10, 9/10, 3/10, 0/10, and 0/10 respectively. Based on this data, we 
decided to inject 500,000 cells for my experiment so that the maximum number of mice 
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could form brain metastases by end of the 9-week period, when all the mice, irrespective 
of treatment group, were sacrificed.  
D. Statin and Whole Brain Irradiation (WBI) treatment plan: 
Four weeks after cell injection, mice were irradiated with 4 Gy, 6 Gy, 8 Gy, 10 Gy 
or 9 Gy in 3 fractions according to the experimental plan discussed in the results section 
(S.K., R.L.). From our lab’s unpublished data, we knew that delaying WBI beyond 21 days 
after cancer cell injection was not sufficient to reduce the incidence of brain metastasis 
[unpublished data]. To treat established brain metastases with a radiosensitizer 
(simvastatin) and WBI, we set our treatment time 4 weeks after cell injection (treatment 
setting). From the initial dose-finding experiments, 10 Gy was chosen as the highest 
tolerated dose and used for the first simvastatin-plus-WBI experiment (S.K.). The highest 
tolerated dose was defined as the highest dose at which there was no radiation-induced 
brain necrosis, which was confirmed by HE staining and pathologist examination. We 
chose the highest tolerated dose for our experiments as this was more logistically feasible 
and cost-effective for the proof of concept of combining simvastatin plus WBI. For our 
second combination study, simvastatin was used with hyper-fractionated (9 Gy in 3 
fractions) WBI dose delivered on days 29, 30, and 31 (3 Gy on each day) after cancer cell 
injection (S.K., R.L.).  
For WBI, mice were placed in an anesthesia inhalation chamber containing 
isoflurane (S.K., R.L.). Anesthetized mice were transferred to the stage in the X-RAD 225 
Cx small-animal irradiator ((Figure 1), PRECISION X-RAY, North Branford, CT, USA) (S.K., 
R.L.). The stage is used to image, plan treatment, and treat each mouse separately. The 
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stage contains a nose cone through which the mice receive constant supply of isoflurane 
to keep them anesthetized. After the mouse was placed on the stage, a scout cone-beam 
computer tomography (CT) image was taken for each of them with a 2.0-mm aluminum 
filter at 40 kVp and 2.50 mA to manually set the isocenter (S.K.).  
The treatment plans were developed by MD Anderson North Campus small-
animal imaging core technologists with PilotXRAD 1.10.4 software and was used for 
irradiating all mice. Different treatment plans were used for single WBI dose of 4 Gy, 6 
Gy, 8 Gy, 10 Gy or 9 Gy in 3 fractions (S.K.). Mice were treated with an isocentric technique 
with equally weighted, opposed lateral 225 keV photon beams using circular fields 
(shaped to 15 mm diameter with a copper collimator) using a 0.3 mm copper filter to 
remove ultra-low-energy photons (S.K.). For example, for a single fraction of 10 Gy 
irradiation, mice received 5 Gy WBI each from two opposing fields that are 180 degrees 
from each other. A cone beam CT was taken for each animal prior to treatment to 
facilitate target localization (S.K.). Fields were positioned to minimize irradiating the oral 
cavity and pharynx. The nominal treatment dose (normalized to 100%) was prescribed to 
the midplane, assuming a depth of 6 mm from the surface of the animal to the isocenter. 
X-rays were delivered at 225 kVp and 13.0 mA with the following exposure time from each 
field of radiation (S.K.) 
For 10 Gy – from each field 5 Gy was delivered for 103.88 s 
For 8 Gy – from each field 4 Gy was delivered for 83.11 s 
For 6 Gy – from each field 3 Gy was delivered for 62.33 s 
For 3 Gy – from each field 1.5 Gy was delivered for 31.16 s 
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For the first simvastatin-plus-WBI experiment (Figure 2), a total of 70 mice was 
used. The control consisted of 15 mice treated with neither statin nor with WBI and given 
only plain water. Based on the previous dose of simvastatin that was used in mouse 
studies from our lab [25], 15 mice received simvastatin alone in their drinking water (15 
mg/kg/day). 15 mg/kg/day dose is approximately 25 times more than the amount of 
simvastatin (40 mg tablet on average) taken orally by a dyslipidemia patient weighing 70 
kg. Simvastatin-treated mice began receiving water supplemented with simvastatin at a 
concentration of 0.04 mg/mL after four weeks of cancer-cell injection. The simvastatin-
supplemented drinking water was changed weekly until all mice were euthanized (S.K., 
R.L.). 20 mice received 10 Gy WBI alone and 20 mice received 15 mg/kg/day statin plus 
10 Gy WBI (S.K., R.L.). Mice were euthanized 5 weeks after radiation treatment (S.K., R.L.).  
Based on previous experiments carried out in our lab [13], we knew that maximum 
number of mice in the control group (70 – 100%) will form brain metastasis after 9 weeks 
of injecting 500,000 IBC cells through the tail vein. We therefore delivered WBI after 4 
weeks of cancer injection (treatment setting) and sacrificed all the mice after 5 weeks of 
radiation (total 9 weeks). We did not perform survival analysis, in which we sacrifice each 
mouse as it becomes moribund, because our primary goal was to determine if adding 
simvastatin to WBI reduces the incidence of brain metastasis at a particular time point (5 
weeks after cancer cell injection) rather than if simvastatin increased the survival of mice 
with brain metastases. Brain metastatic status was determined by fluorescent microscopy 
(S.K., S.S.). 
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For the second in vivo simvastatin plus WBI experiment, the following changes 
were made from the above experiment plan (Figure 3): 
1) We hypothesized that the bioavailability of simvastatin in the brain at the time 
of irradiation is important for their synergistic effects. We therefore hypothesized 
arbitrarily that starting simvastatin treatment one week prior (from day 22 after cancer 
cell injection) to the radiation treatment (day 29, 30, 31) would create synergistic effects 
between simvastatin and WBI (S.K., W.W.).  
2) Fractionated 3 Gy radiation for three consecutive days (day 29, 30, 31) was 
given to test the hypothesis that simvastatin could affect the sub-lethal repair machinery 
of the cell and have synergistic effects with radiation-induced damage (S.K., S.S.).  
E. Fluorescent Based Stereo Microscopy  
Five weeks after WBI, all mice were sacrificed and brains were collected in cold 
PBS (S.K., R.L.). Brain were imaged using a fluorescent-based stereo microscope (Nikon 
AZ100, Tokyo, Japan) at 20X magnification and 35% of maximum excitation laser 
intensity (as 100% produced too much background/noise) for identifying metastatic 
lesions based on the GFP intensity level of the IBC3 cells (S.K., S.S.). Bright-field images 
without fluorescence were taken to capture the “structure” of each mice brain (S.K., 
S.S.).  
Three researchers, who were not involved in imaging the mice brains, counted 
the number of brain metastatic lesions per mouse from the stereo microscope GFP 
images. They were blinded to the treatment groups. For the incidence of brain metastatic 
lesions (binary variable—presence or absence), the saved images of the top and bottom 
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of the brain were used and the three researchers’ counts were plotted individually. For 
the number of brain metastatic lesions, the images of the top and bottom the brain were 
used and arithmetic mean of three researchers’ counting were plotted for each 
treatment group. If two metastatic lesions coalesced without clear separation, they were 
counted as one.  
For tumor burden, the threshold between actual GFP signal and background was 
set initially using ImageJ software (S.K., S.S.). The threshold was set using a mouse brain 
image from the control group and visually adjusting the background such that only brain 
metastatic lesions were visible with minimum background signal (S.K., S.S.). The same 
threshold intensity value was applied for all the images automatically using the ImageJ 
macro program (S.K., S.S.). Tumor burden was calculated by dividing the integrated (top 
and bottom) GFP pixel area by the integrated total brain area (S.K.). 
F. Statistical Analysis 
Statistical calculations were performed in GraphPad Prism 7 and SPSS v24. All 
tests were two-sided, and p-values less than 0.05 were considered statistically significant 
(S.K., S.S.).  
G. Tumor burden and Number of Brain Metastatic lesions data analysis  
Inter-rater reliability was calculated using the two-way random intraclass 
correlation coefficient (ICC) for average measures (S.S.). The number of metastatic 
lesions and tumor burden were compared pairwise using the non-parametric Dunn’s 
multiple comparisons test (S.K.).  
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H. Brain metastasis Incidence data analysis  
Inter-rater reliability was calculated using Fleiss’ Kappa coefficient for binary 
categorical measures (S.S.). Binary incidence of brain metastasis was compared using the 
Fisher-Freeman-Halton test separately for each rater’s observation (S.S.). 
A).                                                                                      B).                      
 
C). 
 
Figure 1: Mouse whole-brain irradiation setup. A) X-RAD 225Cx, an irradiator 
dedicated to small-animal irradiation was used for mouse whole-brain irradiation. B) Mice 
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were kept anesthetized using isoflurane through the nose cone outlet present in the 
machine. C) A scout cone-beam CT image was used to set the isocenter, and a copper 
collimator 15-mm in diameter (Bottom panel of B)) was used to define the treatment 
field, shown as a red circle in the software. The above figure was adopted from the thesis 
work of Dr. Dan Smith, Ph.D. student from the Woodward lab. 
Recommended Citation 
Smith, Daniel L., "Prophylactic Cranial Irradiation Reduces the Incidence of Brain 
Metastasis in a Mouse Model of Metastatic Breast Cancer" (2015). UT GSBS Dissertations 
and Theses (Open Access). 613.   
http://digitalcommons.library.tmc.edu/utgsbs_dissertations/613 
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Figure 2: Statin-plus-10 Gy single-dose WBI experimental design. 500,000 GFP-
labelled MDA-IBC3 cells per mouse were injected intravenously through the tail vein of 
70 SCID-Beige mice. Four weeks after cell injection, a 10 Gy single WBI dose was 
administered to 40 mice (2 groups.) Statin treatment was started immediately after 
radiation treatment for 35 mice (2 groups) and continued for 5 weeks. At the end of 5 
weeks after radiation treatment, mice from all four groups were sacrificed and their 
brains and lungs were collected to identify metastatic lesions.  
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Figure 3: Statin-plus-9 Gy WBI dose given in 3 fractions experimental design. 
500,000 GFP-labelled MDA-IBC3 cells per mouse were injected intravenously through the 
tail vein of 74 SCID-Beige mice. Four weeks (on Day 29, 30, 31) after cell injection, a 9 Gy 
WBI dose in 3 fractions was administered to 38 mice (2 groups). Statin treatment was 
started for 37 mice (2 groups) one week before the first radiation dose (from Day 22) and 
was continued for 5 weeks after irradiation. At the end of 5 weeks after radiation 
treatment, the mice from all four groups were sacrificed and their brains were collected 
to identify metastatic lesions.  
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2.4 Results: 
A. Optimization of whole brain radiation dose in SCID-beige mice brain metastasis 
model 
A lab member had previously performed an in vivo experiment combining statin 
plus 10 Gy whole brain radiation treatment (WBRT) in a SCID-beige brain metastasis 
mouse model. The group treated with simvastatin plus radiation had lower incidence 
of brain metastases compared to the other treatment groups (no treatment, 
simvastatin alone, and 10 Gy alone) (Table 1.) While the combination therapy worked 
as expected, supporting our hypothesis, mice had to be sacrificed much earlier (10 days 
after radiation treatment) because they were sick. The original planned time point for 
sacrificing mice was 5 weeks after radiation treatment. Of note, when we examined the 
HE stains of the no-treatment and radiation-alone groups, there was no brain toxicity 
(Figure 4, 5) in any of the mice. One possible reason for these outcomes is mucositis of 
the tongue caused by misdirected delivery of WBI. Since tongues were not collected 
from this experiment, that possibility could not be ruled out.  
 
Figure 4: Representative H&E images of no-treatment and 10-Gy WBI mice with 
brain metastases. Mice with no treatment or 10 Gy WBI showed normal brain 
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architecture and did not have any necrosis or lymphatic damage. Images were taken at 
20X magnification (50% magnified using Leica’s Aperio ImageScope software)  
 
Table 1: Simvastatin reduces brain metastasis incidence 10 days after WBI and 
31 days IBC cell injection. The group treated with simvastatin plus radiation had a lower 
incidence of brain metastases compared to the other treatment groups (no treatment, 
simvastatin alone and 10 Gy alone) (p = 0.002, Cochran trend test). Courtesy of Dr. Jay 
Reddy, previous member of the Woodward lab.    
 
Figure 5: Representative H&E image of mice brain with radiation induced 
necrosis. The image shows a necrotic area (no cells) caused by radiation. The necrotic 
region is typically covered by a region which undergoes gliosis to cover the damaged 
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region. Gliosis process involves the proliferation or hypertrophy of different types of glial 
cells, namely astrocytes, microglia and oligodendrocytes.  
There was no other study which had previously published a tolerated whole-
brain radiation dose in SCID-beige mouse model. I optimized the whole- brain radiation 
dose in SCID-beige mice using the following experiments: 
Experiment 1:  1-year-old SCID-beige mice were irradiated with an 8-Gy single 
dose (3 mice per group), a 6-Gy single dose (2 mice per group) and a thrice-fractionated 
dose of 3 Gy (3 mice per group). No cancer cells were injected into these mice. We 
used 1-year-old mice for logistical reasons, i.e. to help me learn how to 
administer WBI using unused old mice available in our animal facility. We did not 
use 1-year-old mice to study age-related brain toxicities. We wanted to identify 
the optimal radiation dose with least toxicity to the normal brain. 5 weeks after 
irradiation, mice were sacrificed and brains were dissected. H&E staining of all 
irradiated brains revealed that they had normal brain architecture and did not have 
any necrosis or lymphatic damage (Figure 6). H&E staining results were confirmed with 
an expert pathologist at MD Anderson Cancer Center.  
Figure 6: Representative H&E images of 1-year-old SCID-beige mice irradiated with 
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different WBI doses. Mice irradiated with single dose of 8 Gy, 6 Gy and 9 Gy in 3 
fractions showed normal brain architecture and did not have any necrosis or lymphatic 
damage. Images were taken at 20X magnification (50% magnified using Leica’s Aperio 
ImageScope software)  
Experiment 2. To maintain the same experimental condition as our major in 
vivo experiments (using 70 – 74 mice) we bought 10 SCID-beige mice, and when they 
were 9 weeks old, whole-brain radiation was given to them as follows: a 10-Gy single 
dose (3 mice per group), an 8-Gy single dose (3 mice per group), 6 Gy single dose (2 mice 
per group), and a 9 Gy WBI dose in 3 fractions (3 mice per group). IBC3 cancer cells were 
not injected into any of the above 10 mice. Our major in vivo experiments used 9-week-
old mice since that is standard procedure in our lab and not because of any age-related 
effects [13 and unpublished work from Dr. Dan Smith]. We sacrificed all 10 mice 5 weeks 
after irradiation and collected their brains. H&E staining of all irradiated brains revealed 
that they had normal brain architecture and did not have any necrosis or lymphatic 
damage (Figure 7.) H&E staining results were confirmed with an expert pathologist at 
MD Anderson Cancer Center. Some of the mice had dermatitis after radiation. However, 
these mice recovered from dermatitis upon Baytril antibiotic treatment. This 
experiment’s results were surprising since none of the 10-Gy, whole-brain irradiated 
mice died, unlike in the experiment conducted by a previous lab member (as mentioned 
above), and all 3 mice survived 5 weeks after radiation.  
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Figure 7: Representative H&E images of 9-week-old SCID-beige mice (without 
cancer-cell injection) irradiated with different WBI doses. Normal mice irradiated with 
single dose of 10 Gy, 8 Gy, 6 Gy, and 9 Gy in 3 fractions showed normal brain 
architecture and did not have any necrosis or lymphatic damage. Images were taken at 
20X magnification (50% magnified using Leica’s Aperio ImageScope software.)  
Experiment 3: I wanted to test if creating brain metastases in SCID-beige mice 
would have a different toxicity profile since experiments 1 and 2 were performed 
without cancer-cell injection. We injected 9 SCID-beige mice, 6 weeks old, with 500,000 
GFP-labelled IBC3-GFP-luc cells per mouse through the tail vein. 21 days after cancer 
cell injection (for treatment setting), we irradiated 3 mice with 10 Gy alone, 3 mice with 
8 Gy, and 3 mice with 6 Gy. Seven out of nine mice, irrespective of the radiation dose 
given, developed dermatitis and received Baytril treatment for the same. We had 2 
control mice which were not injected with cancer cells but received 10 Gy radiation 
alone. Interestingly, again all the mice survived 5 weeks after radiation treatment, and 
we sacrificed all 11 mice to collect their brains and check for toxicity. H&E staining of 
all 11 brains revealed that they had normal brain architecture and did not have any 
42 
 
necrosis or lymphatic damage (Figure 8.) H&E staining results were confirmed with an 
expert pathologist at MD Anderson Cancer Center. We therefore chose 10 Gy as the 
maximum tolerated dose among all the doses used in the above experiments for our 
major in vivo studies combining simvastatin with whole-brain irradiation in IBC3 brain 
metastasis SCID-Beige mouse models. We chose the highest tolerated dose as this was 
more logistically feasible and cost-effective for the proof of concept of combining 
simvastatin plus WBI. 
 
Figure 8: Representative H&E images of IBC3 brain-metastasis SCID-Beige 
mouse models irradiated with different WBI dose. 6-week-old SCID-beige mice were 
injected with 500,000 GFP-labelled IBC3 cells per mouse through the tail vein. 21 days 
after cancer cell injection, 3 mice were irradiated with 10 Gy, 3 mice with 8 Gy, and 3 
mice with 6 Gy. All irradiated mice showed normal brain architecture and did not have 
any necrosis or lymphatic damage. It is also interesting to note here that there was a 
dose-dependent effect of WBI on brain metastatic burden. Images were taken at 20X 
magnification (50% magnified using Leica’s Aperio ImageScope software.) 
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B. Combinatorial effects of simvastatin and an optimized whole-brain radiation 
dose in an IBC brain-metastasis mouse model 
  First major in vivo experiment – 10-Gy single WBI dose plus Simvastatin  
General health of treated mice: All 70 mice survived through the 5-week period 
after the 10-Gy radiation treatment. There was significant weight loss and dermatitis in 
all 40 irradiated mice (20 each in radiation-alone and combination group.) Dermatitis in 
the field of irradiation was treated with an ophthalmic ointment. Weight loss was 
managed with gel-pack treatment and mice gained weight slightly after the treatment.  
Tumor burden: 10 Gy WBI alone significantly reduced the brain metastasis 
burden compared to no treatment (p = 0.0324.) Simvastatin alone (p > 0.9999) and the 
combination of simvastatin and 10 Gy WBI (p = 0.1054) did not significantly reduce the 
brain metastatic burden compared to the control. There was no significant difference 
in brain metastatic burden between treatment with 10 Gy alone and combination 
treatment (p > 0.9999) [Figure 9]. 4 out of 15 mice (26.67%) in the no-treatment group 
had close to zero tumor burden. From our lab’s work (13), it is known that the tail-vein-
injection brain-metastasis model has a tumor take rate of 67%. In my current 
experiment, the take rate was 73.33%. Therefore, the number of cells injected was not 
a problem. Simvastatin appears to increase the tumor burden but it is not significantly 
different compared to no treatment. The 10-Gy WBI dose was so effective by itself that 
we might have failed to see any interaction between simvastatin and 10 Gy WBI. This is 
one of the reasons for changing the dose in my second major in vivo experiment.  
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Table 2: Statistical analysis for tumor burden across no-treatment, simvastatin-
alone, 10 Gy WBI–alone and simvastatin–plus–10 Gy WBI treatment groups. Dunn’s 
multiple comparisons test was used to calculate the p-value for each pair of treatment 
groups.  
 
Figure 9: Tumor burden for the no-treatment, simvastatin-alone, 10 Gy WBI–
alone, and simvastatin–plus–10 Gy WBI treatment groups. Tumor burden was 
calculated by dividing the integrated (top and bottom) GFP pixel area by the integrated 
total brain area. 
Incidence: To determine if there were significant differences in incidence 
between different treatment groups, the Fisher-Freeman-Halton test was used to 
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calculate the p-value for each of the three raters separately. All three raters agreed that 
there was no difference in incidence in any of the four treatment groups. Inter-rater 
reliability, measured using the Fleiss’ Kappa coefficient for binary categorical measures, 
was 0.77, indicating substantial agreement between the three raters. The bar graph 
below shows the incidence of brain metastasis and the corresponding p-values for each 
rater separately [Figure 10]. All three raters agreed that there was an increase in the 
incidence of brain metastasis upon treatment with statin alone, but it is not significantly 
different compared to no treatment.  
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Figure 10: Brain metastasis incidence for no-treatment, simvastatin-alone, 10 
Gy WBI–alone and simvastatin–plus–10 Gy WBI treatment groups. The Fisher-Freeman-
Halton test was used to calculate the p-value for each rater separately.  
Number of brain metastatic lesions per mouse: Since incidence is a binary 
measure, we wanted to plot the number of brain metastatic lesions in absolute scale as 
shown below (Figure 11.) Dunn’s multiple comparisons test was used to calculate the p-
value for each pair of treatment groups (Table 3.) The number of brain metastatic lesions 
was not significantly different between any pair of treatment groups. Though not 
significant, there was an increase in the number of brain metastatic lesions with statin 
alone and a decrease in the number of brain metastatic lesions with 10 Gy WBI alone and 
the combination treatment (10 Gy WBI plus simvastatin) compared to no treatment. 
Contrary to our hypothesis, simvastatin addition to 10 Gy WBI increases the number of 
brain metastatic lesions compared to 10 Gy WBI alone. The agreement between three 
raters for average measure such as the number of brain metastatic lesions was calculated 
using two-way intraclass correlation coefficient (ICC). The ICC was calculated to be 0.925 
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with a 95% confidence interval (0.869 – 0.956.) An ICC > 0.9 is considered excellent 
agreement between raters.  
 
Figure 11: Number of brain metastatic lesions for no-treatment, simvastatin-
alone, 10 Gy WBI–alone and simvastatin–plus–10 Gy WBI treatment groups. Each dot 
represents a mouse. Red lines represent the median numbers of brain metastatic 
lesions in each treatment group.  
 
 
Table 3: Statistical analysis for number of brain metastatic lesions per mouse 
across no-treatment, simvastatin-alone, 10 Gy WBI–alone and simvastatin–plus–10 
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Gy WBI treatment groups. Dunn’s multiple comparisons test was used to calculate the 
p-value for each pair of treatment groups.  
 
Tumor burden, incidence, and number of brain metastatic lesions in the four treatment 
groups are represented below (Figure 12.)  
 
Figure 12: Representative fluorescence–bright field overlay images of no-
treatment, simvastatin-alone, 10 Gy WBI–alone and simvastatin–plus–10 Gy WBI 
treatment groups. Each of the four images corresponds to the mouse with the tumor 
burden and number of brain metastatic lesions closest to the arithmetic mean value from 
its respective treatment group. The bright field image was overlaid with the GFP image 
to get both the architecture of the brain and its metastatic lesions.  
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Second major in vivo experiment – 9 Gy WBI dose in 3 fractions plus simvastatin: 
Background and hypothesis: 
From the above combination study, it can be seen that a single, high dose of WBI 
(10 Gy) was so effective by itself that it did not allow statins to sensitize brain metastasis 
to radiation any further in the combination group. We therefore wanted to reduce the 
WBI dose and see if statin radiosensitized and reduced the incidence of brain metastasis 
further in the second major in vivo experiment. For the synergistic effects of statin and 
WBI, we hypothesized that fractionating the dose would give time for tumor cells to 
repair their damage, resulting in synergistic effects.  
In the second in vivo experiment, we gave a 9 Gy WBI dose in 3 fractions on days 
29, 30 and 31 after cancer cell injection. Also, we chose 9 Gy in 3 fractions because it is a 
more clinically relevant dose compared to a single dose of 10 Gy WBI while taking cost 
and logistics into consideration. IBC brain metastasis patients are treated with 30 Gy WBI 
dose given in 10 fractions, and a 9 Gy in 3 fractions dose is equivalent to 6.2 Gy (assuming 
the α/β value of IBC cells to be 4.5.) The α/β ratio describes the ratio of irreparable 
(alpha) to potentially repairable (beta) DNA damage within the linear-quadratic model 
of radiation-induced cell killing. The higher the α/β value, the better the response of cell 
line/tumor to fractionated radiotherapy. Figures 8, 9, and 13 shows a dose-dependent 
reduction of tumor burden and 10 Gy by itself reduced tumor burden significantly. To 
check the combinatorial effects of statin and radiation, we chose a sub-optimal dose (9 
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Gy in 3 fractions ~ 6-Gy single dose) for WBI and checked if statins reduced the incidence 
and brain metastatic burden further when combined with radiation.  
 
Figure 13: WBI dose-dependent reduction of IBC3 brain metastatic burden. GFP 
images taken with Nikon stereomicroscopy.   
Based on our lab’s previous work (26), I knew that reducing intracellular 
cholesterol by adding high-density lipoprotein (HDL) radiosensitizes IBC cells in vitro. Our 
lab had found an increase in the initial number of γH2AX foci compared to no treatment 
when HDL is added, possibly indicating that HDL increased the DNA damage by unknown 
mechanisms. More importantly, HDL-added IBC cells had persistent γH2AX foci 
formation, indicative of persistent DNA damage and lack of DNA repair. As simvastatin 
also reduces intracellular cholesterol by shutting down its synthesis, I hypothesized 
simvastatin would inhibit the repair mechanisms of IBC cells, which try to clear the 
damage caused by radiation, resulting in synergistic effects of radiation and simvastatin 
(Figure 12.) Interestingly, the above hypothesis was supported by a recent paper from 
another group (27), which showed statins (including simvastatin) delay DNA-repair 
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mechanisms and cause cellular senescence after irradiation. In vivo experiments in the 
above paper irradiated primary breast tumors and melanoma in mice with pitavastatin. 
It was not determined whether statins will radiosensitize IBC brain metastasis to whole-
brain irradiation.  
In the previous experiment, we also gave simvastatin immediately after radiation. 
We hypothesized that simvastatin may require some time to reach the brain and may 
not be present immediately when the cells try to repair their damage. To maximize the 
bioavailability of simvastatin in the brain after radiation, we arbitrarily started 
simvastatin treatment one week before radiation. All other parameters such as the 
number of cancer cells used for injection, mode and duration of statin delivery, and so 
on were kept constant between the first and second experiment.  
 
Figure 14: Hypothesis for hyper-fractionated low dose WBI for combinatorial 
effects with simvastatin. The graph was drawn with following α/β value – 4.5 for the 9 
Gy in 3 fractions and 10-Gy single WBI dose. We hypothesized that with the addition of 
simvastatin, damage will become increasingly irreplaceable since simvastatin will inhibit 
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the sub-lethal repair mechanisms after radiation; i.e., the α/β value will increase. 
Simvastatin plus 9 Gy in 3 fractions was drawn assuming the α/β value would increase to 
7. The linear extrapolation of the curves (see dashed lines), sometimes called the 
“effective survival curve,” help demonstrate the presence of a shoulder.  
Results for 9 Gy WBI dose in 3 fractions plus simvastatin: 
Tumor Burden: The sub-optimal WBI dose, 9 Gy in 3 fractions alone, did not 
significantly (p = 0.1378) reduce the brain metastatic burden compared to no treatment 
as predicted. But addition of simvastatin to the sub-optimal WBI dose did not 
radiosensitize and reduce brain metastatic burden significantly compared to radiation 
alone (p > 0.9999) or even no treatment (p = 0.2519). This is shows that simvastatin does 
not radiosensitize IBC3 HER2+ brain metastases to WBI in our model. Interestingly, when 
simvastatin is given one week before radiation, there is no increase in the brain 
metastatic burden, which was observed in the previous experiment, compared to no 
treatment (p > 0.9999.) From the no-treatment tumor-burden values (Figure 15), it can 
be observed that the dynamic range of tumor-burden values across 18 mice was low and 
many mice had close to zero tumor burden, possible reasons our model is limited in 
understanding the combinatorial effects of simvastatin and WBI.  
 
Table 4: Statistical analysis for tumor burden across groups of no-treatment, 
simvastatin alone, 9 Gy WBI dose given in 3 fractions alone, and combination treatment. 
Dunn's multiple comparisons test Adjusted P Value
No Treatment vs. Statin alone >0.9999
No Treatment vs. 3*3Gy alone 0.1378
No Treatment vs. Statin plus 3*3 Gy 0.2519
3*3Gy alone vs. Statin plus 3*3 Gy >0.9999
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Dunn’s multiple comparisons test was used to calculate the p-value for each pair of 
treatment groups.  
 
Figure 15: Tumor burden for no-treatment, simvastatin alone, 9 Gy total WBI 
dose given in 3 fractions alone, and the combination group. Tumor burden was 
calculated by dividing the integrated (top and bottom) GFP pixel area by the integrated 
total brain area. 
Brain metastasis Incidence: To find if there was significant difference in incidence 
between different treatment groups, the Fisher-Freeman-Halton test was used to 
calculate the p-value for each of the three raters separately. All three raters agreed that 
there was no difference in brain metastasis incidence between any of the four treatment 
groups. Inter-rater reliability, measured using Fleiss’ Kappa coefficient for binary 
categorical measures, was 0.824 (95% CI 0.690 – 0.957.) Anything over 0.8 is considered 
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“almost perfect agreement” between three raters. The bar graph below shows the 
incidence of brain metastasis and corresponding p-values for each rater separately 
(Figure 16.) All three raters agreed that there was an increase in the incidence of brain 
metastasis upon treatment with statin alone, but it is not significantly different 
compared to no treatment. This was observed in the previous experiment as well. 
Surprisingly, though not significant, there was an increase in incidence of brain 
metastasis upon treatment with 9 Gy WBI in 3 fractions alone and upon combination 
treatment compared to no treatment separately. This observation needs further 
investigation to understand why radiation would increase the incidence of brain 
metastasis.  
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Figure 16: Brain metastasis incidence for no-treatment, simvastatin alone, 9 Gy total 
WBI dose given in 3 fractions alone, and the combination group. Fisher-Freeman-Halton 
test was used to calculate the p-value for each rater separately. 
Number of Brain metastasis lesions per mouse: Since incidence is a binary 
measure, we wanted to plot the number of brain metastatic lesions in absolute scale as 
shown below (Figure 17.) Dunn’s multiple comparisons test was used to calculate the p-
value for each pair of treatment groups (Table 5.) The number of brain metastatic lesions 
were not significantly different between any pairs of treatment group. Though not 
significant, there was an increase in the number of brain metastatic lesions when mice 
were treated with statin alone and a decrease in the number of brain metastatic lesions 
when mice were treated with 9 Gy total WBI dose alone given in 3 fractions of 3 Gy 
compared to no treatment. The combination of 9 Gy total WBI and simvastatin had 
almost the same number of brain metastatic lesions compared to no-treatment. 
Contrary to our hypothesis, simvastatin combined with 9 Gy of WBI increased the 
number of brain metastatic lesions compared to radiation alone. The agreement 
N
o
 T
re
a
tm
e
n
t
S
ta
t i
n
3
*3
G
y
 a
lo
n
e
 
S
ta
t i
n
 +
 3
*3
G
y
0 .0
0 .5
1 .0
1 .5
T re a tm e n t g ro u p s
In
c
id
e
n
c
e
M e ta s ta s e s
N o  M e ta s ta s e s
B ra in  m e ts  in c id e n c e  b y  R a te r  3
Rater 3, P=0.25 
 
56 
 
between the three raters for their measured averages was calculated using the two-way 
intraclass correlation coefficient (ICC). The ICC was calculated to be 0.971 with a 95% 
confidence interval (CI = 0.957 – 0.981). An ICC > 0.9 is considered excellent agreement 
between raters. 
 
Figure 17: Number of brain metastatic lesions for groups of no-treatment, 
simvastatin alone, 9 Gy total WBI dose given in 3 fractions alone, and combination 
treatment. Each dot represents a mouse. Red lines represent the median number of 
brain metastatic lesions in each treatment group.  
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Table 5: Statistical analysis for the number of brain metastatic lesions per 
mouse across groups of no-treatment, simvastatin alone, 9 Gy total WBI dose given in 
3 fractions alone, and combination treatment. Dunn’s multiple comparisons test was 
used to calculate the p-value for each pair of treatment groups.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Dunn's multiple comparisons test Adjusted P Value
No Treatment vs. Statin >0.9999
No Treatment vs. 3*3Gy 0.1399
No Treatment vs. Statin + 3*3Gy >0.9999
3*3Gy vs. Statin + 3*3Gy 0.8168
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2.5 Discussions and Future Directions 
Combining simvastatin with either a fractionated or single WBI dose did not 
reduce the incidence of brain metastasis. There could be several reasons for this result. 
First, a single high dose of radiation (10 Gy WBI) almost completely eradicated most brain 
metastatic lesions, possibly limiting further radiosensitization of brain metastases by 
statins. A sub-optimal fractionated dose (9 Gy WBI in 3 fractions) did not reduce the 
tumor burden or incidence of brain metastasis and statins did not radiosensitize them. 
The dynamic range for the dose of radiation seems to be very small—a high dose is 
effective and a sub-optimal dose has no effect. It would be interesting to observe what 
happens to the combination of an 8-Gy single WBI dose with simvastatin or a 12 Gy WBI 
dose  given in 4 fractions with simvastatin.   
Second, similar to the finding of Efimova EV et. al, Mol Cancer Ther. 2018 (27), 
our results did not show any effect of statins themselves on brain metastasis reduction. 
The radiosensitization by statins in the above paper is dependent on damage caused by 
radiation; i.e., only radiated samples have synergistic effects with statin. These data also 
support our hypothesis that statins radiosensitize cells by inhibiting DNA repair 
mechanism. 
Third, though 10 Gy WBI reduced the burden significantly, reducing incidence, i.e 
eradicating brain metastasis completely, is a challenging task. Radiation caused 
substantial cell killing, but leaving even few radio-resistant cells to survive would not 
reduce the incidence. Radioresistance is major problem in the clinic and our animal 
model reflects this fact. Because of the difficulty in finding a radiosensitizer, there is 
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currently no drug approved by the FDA for whole-brain radiosensitizing of brain 
metastases.  
Third, statins prevent plaque formation but have no benefit for patients with high 
cholesterol deposition in their blood vessels. Statin is therefore known to be a 
preventative drug in individuals at high risk for atherosclerosis and advanced vascular 
disease and not very effective for later stages of the disease. My data also suggest that 
statin has no impact on developed brain metastases (4 weeks after cancer cell injection) 
but could be effective in the absence of clinically apparent metastatic disease based on 
our lab’s published data (25). In this investigation, our lab showed that pre-treating cells 
with statin in vitro and then injecting the cancer cells into mice prevented their ability to 
form metastasis both in orthotropic and experimental tail-vein metastasis models. 
Injecting SUM149, a triple-negative IBC cell line, in vivo through the tail vein first and then 
treating with simvastatin one week after cancer cell injection reduced metastasis 
formation. In this paper, simvastatin was shown to upregulate FOXO3a, a tumor 
suppressor, and have a therapeutic effect.  Whether this tumor suppressor has any role 
in radiosensitization or repair after radiation damage is yet to be explored. These 
published data suggest that statin is effective in preventing or treating brain metastases 
at an early stage and not when brain metastases are fully developed, as is the case in my 
experiments. Simvastatin by itself could be therefore used as a drug to treat breast cancer 
patients, who are at high risk for forming brain metastases, before they present with 
clinically apparent metastatic disease.  
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It is also interesting to note the difference in my experimental results compared 
to the experiment summarized in Table 1. The previous experiment results (Table 1) show 
that addition of statins to WBRT decreases metastatic incidence after 10 days of radiation 
treatment. Assuming the health status of mice had nothing to do with the observed 
experiment results, these results show that statin delayed the progression of brain 
metastasis when combined with radiation treatment. This observation can be explained 
by statin’s role in improved radiosensitivity and reduced proliferation of brain metastatic 
cells when radiation is given at an earlier time point (21 days) and mice were sacrificed 
10 days after radiation treatment. Similar effects of statin do not happen at a later time 
point like what was observed in my experiments.  
1) Improved radiosensitivity: radiation is more likely to kill most of the metastatic 
cells when there are fewer to begin with. Statins may also be able to improve 
radiosensitivity to a degree that would allow complete eradication. Since radiation does 
not kill all cells, over the 5-week period radio-resistant cells would have proliferated, 
forming the metastatic lesions seen with stereo-microscopy. To find out at what time 
point there would be no difference in incidence between the radiation-alone and 
combination-treatment groups, investigators may consider observing what happens 
between 10 days and 5 weeks after irradiation, i.e. sacrificing mice at the third or fourth 
week after radiation.  
2) Reduced proliferation: statins reduce the fraction of cells entering S phase (25), 
and thus appear to slow the proliferation of tumor cells. In the previous experiment, the 
metastatic lesions seen at 10 days after radiation treatment were tiny. It is possible that 
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statins only slowed cell growth so at that particular time point we saw many fewer 
metastatic lesions, but after a longer period of time they may have become apparent.  
My experiment results are supported by a randomized clinical trial combining 
simvastatin and WBI in patients with brain metastasis (28). The primary tumors of these 
brain metastasis patients were either lung or breast cancers. Whether IBC brain 
metastasis patients were included in their trial within the group of breast cancer patients 
was not mentioned in the paper, and the trial was not powered to have sufficient 
numbers of patients surviving until the endpoint of the study. Because of the uncertainty 
in the statistical results of this clinical trial, we decided to continue testing our hypothesis 
in our IBC brain metastasis mouse model and obtained results similar to those of the 
clinical trial, i.e. simvastatin does not radiosensitize brain metastases to WBI.  
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Chapter 3: Mass spectrometry based tissue imaging to understand the cholesterol 
distribution and its perturbations by simvastatin in brain metastatic lesions and its 
microenvironment 
3.1 Background: 
Mass spectrometer is an important instrument that is used to identify and 
confirm a biomolecule, or understand structure of a biomolecule etc. Using liquid 
chromatography coupled with a mass spectrometer (LC-MS), whole proteome and 
metabolome of different biological samples can be identified. While LC-MS is useful to 
understand whole proteome level changes of an entire sample, it lacks the ability to 
capture spatial heterogeneity in distribution of a biomolecule and understand how 
different cells respond to a certain treatment condition. This limitation is overcome by a 
technology called Mass Spectrometry Imaging (MSI) which provides spatial information 
of many biomolecules present at a particular pixel location of a sample.  
The specific type of MSI instrument used in this study was a Matrix-Assisted Laser 
Desorption Ionization (MALDI) Mass Spectrometry (Center for Radiation Oncology 
Research (CROR) MSI core). This instrument is a high-resolution mass spectrometer 
specifically configured for imaging biological and chemical materials. Since most 
abundant compounds detected in a tissue will fall in the range of 50-2000 m/z values, 
MSI data is typically acquired for this range of m/z values using the mass spectrometer. 
The detailed procedure of how this technology works is mentioned in the materials and 
methods section below.  
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 Using the MSI technology, I wanted to understand cholesterol distribution in 
different cell types present in brain metastasis microenvironment and how simvastatin 
perturbs this distribution. From the paper (22), I hypothesized that perturbing the 
cholesterol levels in astrocytes and brain metastatic cells will have therapeutic benefit 
for IBC brain metastasis. Also, there is no other study which has used MSI to understand 
whole metabolomic differences between IBC brain metastatic cells and the adjacent cells 
present in its microenvironment. By overlaying the H&E images with MS images, one 
could understand the cholesterol distribution in different cell types of brain and 
heterogeneity in perturbation of simvastatin.   
3.2 Materials and Methods  
(*- Swaminathan Kumar, **- Richard Larson, ***- Shane Stecklein) 
A. Sample Preparation: 
Mice was anesthetized and cervical dislocation was performed (S.K*., R.L.**). 
Then mice brains were removed (S.K., R.L.) and kept in PBS before imaging it under 
fluorescent based stereo microscopy (S.K., S.S.***). Brain tissue with GFP positive (IBC3-
GFP cells) metastatic lesions were sectioned into slabs using a scalpel, flash frozen with 
dry ice, and then stored at -80°C until needed (S.K.). Instead of storing the tissue in 10 % 
formalin, I flash froze the tissue on dry ice without any chemical because formalin or any 
other chemical can interfere due to its abundance and mask the actual signal in the mass 
spectrometry imaging data. Using a cryotome, the frozen tissue was cut into 10 µm 
thickness and 31 such serial sections were placed in 31 glass microscope slides 
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(Experimental Radiation Oncology (ERO) core). 10 µm was used because it is the ideal 
thickness for optimized MS parameters for the imaging mass spectrometer 
instrument. For each tissue, every 5th slide (Slide No. 1, 6, 11, 16, 21, 26, and 31) was 
stained with Hematoxylin and Eosin (H&E) to verify the presence of brain metastatic 
lesions (ERO core). Slides with at-least one metastatic lesion were chosen for tissue mass 
spectrometry based imaging (S.K.). These slides were kept frozen at -80°C until ready for 
matrix application.  
The Shimadzu IM Layer, an automated sublimation matrix applicator was used to 
coat 2, 5 dihydroxybenzoic acid (for positive mode) on the tissue sections for 30 min 
(CROR MSI core). The resulting coated slides were subjected to a rehydration step in a 
heated humidifying chamber for 3 minutes using 1 ml of 9:1 ratio of water and methanol 
solution respectively (CROR MSI core).  
B. Mass Spectrometry Imaging (MSI) procedure  
Cryo-sectioned slides were imaged using Waters Synapt G2-Si with Imaging MALDI 
Mass Spectrometry (CROR MSI core). Imaging of tissue mounted on microscope slides is 
achieved using a 2.5 KHz NdYAG solid state laser rastered across the tissue sample, giving 
a chemical composition profile on each corresponding spatial coordinate [Figure 16]. 
These mass spectral information are collated by the HD Imaging (HDI) software to 
produce a chemical image that can be correlated to the sample’s histological profile (from 
H&E staining of adjacent tissue slide) (S.K.).  
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Prior to loading the coated slide into the mass spectrometer, the slide was 
scanned using an EPSON scanner for mapping the interested areas into the HDI software 
(CROR MSI core). The area is selected by the operator visually based on the borders of the 
brain tissue (CROR MSI core). The laser power was set to 250 (arb units) with 300 laser 
shots per pixel data (CROR MSI core). The laser raster step was set to 60 µm to match the 
oval shaped laser spot size of 60 µm (CROR MSI core). Prior to acquiring the data, the 
instrument was checked for mass accuracy and was calibrated using red phosphorus (36) 
(CROR MSI core). Since red phosphorus (MW= 30.974) can form clusters of 1-89 such 
molecules by laser desorption ionization in positive mode, they can be used as a standard 
to calibrate the machine for mass accuracy up to 3000 m/z values.  
C. Mass Spectrometry Image analysis for cholesterol distribution: 
After acquisition, the HDI software automatically processes the raw data into a 
collection of images (S.K.). Each image corresponds to a particular m/z ion distribution 
over the entire tissue. M/z value represents the mass/charge ratio of each molecule which 
is known from the literature and is stored in the human metabolome database. The 
software matches each m/z value with a particular molecule of interest by searching the 
database (S.K.).  
Since one of the function of simvastatin is to reduce the cholesterol biosynthesis, 
I checked for cholesterol distribution across all the four treatment groups. The preferred 
ion state (more abundant and stable form) of cholesterol {[M+H-H2O]+} was chosen as 
the m/z value, 369.35 (29), and the corresponding images for each treatment group was 
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downloaded from the software (S.K.). 3-6 biological replicates (different mice) were 
imaged for each treatment group (CROR MSI core).  
Tumor burden value was calculated as mentioned in chapter 2. Spatial distribution 
of Cholesterol across the brain parenchyma was observed visually from MSI of the brain 
slides with metastatic lesions (S.K.). Tumor burden and spatial distribution of cholesterol 
was compared to see if there was any correlation (S.K.). Cholesterol distribution was not 
normalized to any standard molecule and the absolute value of cholesterol at each pixel 
is reported in Figure 17, 18, 19 and 20. The dynamic range of cholesterol was 0-50000, 
which was kept constant in all the four figures (S.K.).  
 
 
Figure 18: Mass Spectrometry Imaging work flow. The frozen tissue slide is 
coated with 2, 5 dihydroxybenzoic acid for 30 minutes and then 2.5 KHz NdYAG solid state 
Work flow of MALDI Mass Spectrometry Imaging 
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laser is rastered across the tissue sample to acquire the chemical composition profile on 
each corresponding spatial coordinate. Mass spectral information is collated by HDI 
software to produce a chemical image for each m/z ion value that can be correlated to 
the sample’s histological profile obtained from the adjacent tissue slide stained with H&E.  
3.3 Results  
A. Cholesterol distribution in brain metastasis and its surrounding microenvironment 
in the no-treatment group.  
  The preferred ion state (most abundant and stable state) of cholesterol          
{[M+H-H2O]+} was chosen as the m/z value, 369.35, and the corresponding chemical 
image was downloaded for detecting the distribution of cholesterol across the brain 
sections. The below image [Figure 17] suggests that overall cholesterol distribution across 
each brain section is low in the no-treatment group compared to radiation treated groups 
[Figure 19, 20]. From an unpublished microarray data from our group, I found out that 
the cholesterol biosynthesis pathway genes were upregulated in brain metastasis 
compared to lung metastasis. So I hypothesized that cholesterol level will be more in 
untreated brain metastasis but the results were opposite. In the future, the above 
microarray data and MSI data can be correlated for only after imaging the metastatic 
lesions of lung tissue. Cholesterol levels were lower in brain metastatic lesions compared 
to the adjacent normal brain parenchyma visually. We were not able to quantify this 
observation because the signal of cholesterol is in the noise range (i.e. below 10 % of 
highest intensity ion). Ubiquitously present molecules like Phosphatidylcholine was 
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present above the noise range across all four treatment groups. Also, the tumor burden 
did not correlate with the level of cholesterol present in the brain parenchyma or in the 
brain metastatic regions.  
 
Figure 19: Cholesterol distribution in the brain parenchyma of no-treatment group 
(N=4). The above four brain sections were from four different mice which was not treated. 
Scale bar of intensity heat map were kept constant across all four treatment groups          
(0-50000) to visually compare the cholesterol distribution.  
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B. Cholesterol distribution in brain metastasis and its surrounding microenvironment in 
the statin alone treated group.  
Out of five mice which were imaged using mass spectrometry from the statin 
alone treated group, four of them had low cholesterol level compared to the no-
treatment group [Figure 18]. This data suggests that simvastatin inhibited cholesterol 
biosynthesis (known role of statins) and reduced the cholesterol levels in the entire brain 
parenchyma as simvastatin is not specific to brain metastatic lesions (entire imaged area). 
One mouse had more cholesterol levels in the brain parenchyma and could be considered 
as an outlier. The tumor burden did not correlate with the cholesterol levels in the brain 
parenchyma or the brain metastatic lesions in the statin alone treated group as well.   
 
Figure 20: Cholesterol distribution in the brain parenchyma of statin alone treated 
group (N=5). The above five brain sections are from five different mice. Scale bar of 
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intensity heat map were kept constant across all four treatment groups (0-50000) to 
visually compare the cholesterol distribution.  
C. 10 Gy whole brain irradiation alone and 10 Gy WBI plus statin increases the level of 
cholesterol distribution in the brain parenchyma.  
Three mice brain sections from the 10 Gy radiation alone group [Figure 19] have 
increased cholesterol levels compared to the no-treatment or the statin alone group 
[Figure 17, 18]. Six mice [Figure 20] from the combination group (10 Gy radiation plus 
statin) also have increased cholesterol levels compared to the no-treatment or the statin 
alone group [Figure 17, 18]. The tumor burden did not correlate with the cholesterol 
levels in the brain parenchyma or its metastatic regions in both the radiation treated 
groups.   
 
Figure 21: Cholesterol distribution in the brain parenchyma of 10 Gy alone treated group 
(N=3). The above three brain sections are from three different mice. Scale bar of intensity 
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heat map were kept constant across all four treatment groups (0-50000) to visually 
compare the cholesterol distribution. 
 
Figure 22: Cholesterol distribution in the brain parenchyma of 10 Gy plus statin treated 
group (N=6). The above six brain sections are from six different mice. Scale bar of intensity 
heat map were kept constant across all four treatment groups (0-50000) to visually 
compare the cholesterol distribution. 
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3.4 Limitation of above MSI data: 
A positive control to confirm cholesterol by using a commercial standard of 
cholesterol would strengthen the results further. Though one can match the preferred 
ion state m/z value with the name of the compound by searching through the human 
metabolome database, the molecule could be confirmed further by spiking in a known 
standard of cholesterol into the mass spectrometer. Since we used imaging mass 
spectrometer, the standard would have to be spotted on a slide and then scanned before 
scanning the actual sample of interest. Though the standard will also be identified by its 
m/z value, it could be confirmatory because we spiked the known standard manually. 
Another option is to perform a MS/MS, fragmenting a particular molecule of interest (in 
my case it is cholesterol) by choosing its m/z value. Unfortunately, the machine used for 
my studies cannot perform MS/MS of cholesterol to confirm its chemical composition and 
reconstructing its structure. 
Quantification of total cholesterol ion intensity value in the total imaged area of 
each tissue sample and a statistical test to compare them across different treatment 
groups would be the ideal way to present the above data. Unfortunately, the total ion 
intensity value of the imaged area for each tissue falls below the noise range i.e. below 
10 % of highest intensity ion. This suggests that the sensitivity of the instrument to 
measure less abundant molecules is low or the overall cholesterol distribution is very low 
to be measured by the imaging mass spectrometer used.  
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3.5 Discussions & Future Directions: 
Mass spectrometry based imaging data suggests that even though simvastatin 
reduced the cholesterol levels in the brain parenchyma, it did not cause any therapeutic 
benefit for brain metastasis. This is contrary to what was observed in primary 
glioblastoma cells [22]. Based on this paper [22], we hypothesized that reducing 
cholesterol levels in the brain metastatic cells could have a therapeutic effect 
independent of simvastatin role as radiosensitizer. From our data, this does not seem to 
be the case. Reduction in cholesterol level by simvastatin alone did not have any 
therapeutic effects such as tumor burden reduction or brain metastasis incidence 
reduction.  
Lack of therapeutic benefits from simvastatin could be due to the compensatory 
mechanisms from the cholesterol transport pathway. My hypothesis for the 
compensatory mechanisms is as follows:  
When simvastatin reduces cholesterol levels inside the cell, cell senses its low 
cholesterol level and activates SREBP2 (Sterol regulatory element-binding protein 2) and 
this transcription factor translocates to the nucleus. SREBP2 transcribes LDL-receptor 
(LDLR) which pulls the cholesterol from LDL particles outside the cell thus compensating 
for the cholesterol loss. When there is low cholesterol, SREBP2 also increases HMG-CoA 
reductase (HMGCR) at the level of transcription. Simvastatin inhibits HMG-CoA reductase 
enzyme involved in cholesterol biosynthesis. The balance shift towards simvastatin 
mediated cholesterol reduction or SREBP2 mediated HMGCR increase will decide the net 
74 
 
cholesterol levels inside the cell. While statins are known to reduce blood cholesterol 
levels in patients with dyslipidemia and prevent atherosclerosis, therapeutic efficacy of 
simvastatin to reduce brain metastasis seems not to be the case. 
 The above compensatory mechanisms could be tested at the protein level by 
immunohistochemistry staining of brain tissue samples to further understand why 
simvastatin did not have a therapeutic benefit for brain metastasis. Understanding these 
compensatory mechanisms will help us to identify therapeutic targets that can be 
combined with simvastatin and WBI to overcome the resistance. If LDLR is upregulated 
in the tissue samples treated with simvastatin, then we can use a LDLR inhibitor or 
downstream cholesterol transport inhibitors such as LXR ligand inhibitors (like LXR-623 
(22)) to overcome the resistance by triple combination of the inhibitor with simvastatin 
and WBI.  
For unknown reasons at this point, radiation by itself and with addition of 
simvastatin seems to increase the cholesterol levels in the brain parenchyma. There have 
been reports of ionization effects of radiation on cholesterol present in the lipid rafts (31, 
32, 33). But this needs to be further studied as to how ionizing effect of radiation on the 
cholesterol would increase the downstream signaling and eventually increase the 
cholesterol levels in the brain parenchyma. 
Even though simvastatin did not radiosensitize IBC brain metastasis, one question 
that remains to be answered is “Did simvastatin get inside the brain and performed its 
function of reducing cholesterol”. While my data suggests that simvastatin did reduce 
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the cholesterol levels in the brain parenchyma in statin alone group using MSI data but 
this is not true in simvastatin plus radiation group. This result needs to be further 
validated using two complimentary approaches. – 1). Liquid chromatography mass 
spectrometry (LC-MS) and western blotting of the whole brain tissue lysates.  
Protein lysate from frozen brain tissue samples could be extracted and western 
blotting for HMGCR, SREBP2, and LDLR could be performed. It would be interesting to 
know how these proteins are differentially regulated between no-treatment and 
simvastatin treated samples, and also what happens to these proteins in radiation 
treated samples. While the western blotting experiment may not be a definitive 
experiment to know if simvastatin performed its function, still it would help us to 
understand about the compensatory mechanisms that are acting in the brain once 
simvastatin is added. At the least, I would expect some change in HMGCR, SREBP2 and 
LDLR levels between no-treatment and simvastatin alone treated samples to confirm 
there was some perturbation of cholesterol biosynthesis and transport pathway upon 
simvastatin addition.  
Using LC-MS of brain tissue sample, reduction in mevalonic acid and lanosterol 
levels in simvastatin treated sample compared to no-treatment could be checked. One 
could expect HMG-CoA to be high in simvastatin treated sample, since simvastatin 
prevent HMG-CoA to mevalonic acid conversion by inhibiting HMGCR enzyme. Since 
simvastatin is not specific to any particular cell type, LC-MS of total brain tissue sample 
could definitely help us understand if simvastatin worked or not 
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Ours is the first study (to my knowledge) to generate spatial information of all 
m/z value from 50-2000 Daltons in brain metastatic regions and surrounding brain 
parenchyma by correlating MS images with H&E stained images. This study has 
generated large datasets which could be pursued further to generate hypothesis about 
the role of sterols and other biomolecules in IBC brain metastasis progression. Region of 
interest have been drawn around brain metastatic lesions and the adjacent normal brain 
parenchyma and all the m/z values have been extracted as separate files. Using big data 
analytic techniques, our lab plans to find differentially regulated molecules between 
brain metastatic regions and adjacent normal brain parenchyma and validate 
differentially regulated molecules individually.  
Interestingly, when we checked the distribution of many m/z values in the brain 
using HD Imaging software by eye randomly, we found that some of the m/z values were 
present only in brain metastatic regions and not anywhere else in the brain parenchyma. 
These molecules could be studied in detail and could serve as novel imaging bio-markers 
for identifying brain metastasis or could serve as brain metastasis specific therapeutic 
targets. 
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Chapter 4: Overall Conclusions 
I tested the hypothesis that simvastatin radiosensitizes MDA-IBC3 brain 
metastasis to whole brain radiation. I examined both single fraction whole brain radiation 
(10 Gy) and fractionated whole brain radiation (9 Gy in 3 fractions) with similar results. 
Simvastatin did not significantly reduce the incidence or burden of brain metastases in 
this model when radiation was given four weeks after tumor cell injection. Treatment was 
well-tolerated. Mass spectrometry imaging was performed to determine if simvastatin 
treatment resulted in observable differences in cholesterol between groups. Preliminary 
comparison across images suggests simvastatin treatment reduced overall cholesterol 
levels throughout the brain tissue, however, unexpectedly radiation increased cholesterol 
levels. Therefore, we were unable to determine whether the desired effect on cholesterol 
was achieved in irradiated animals. These data serve as pilot information to develop 
adequate power to investigate this further. If a compensatory increase in cholesterol is 
caused by whole brain radiation, further exploration of adequate manipulation of 
cholesterol for radiosensitization may be warranted. 
There are several limitations to the work described. First, we have only examined 
this hypothesis in one animal model. Our lab previously demonstrated in vitro that 
simvastatin radiosensitizes SUM149 (23), a triple negative (TN) IBC cell line. Among 
different IBC subtypes, TN IBC (9) and HER2+ IBC (10) have the highest propensity to 
metastasize to the brain. SUM149 can form brain metastasis through tail vein injection 
(13). This cell line has BRCA mutation and p53 mutation (34) which could make it sensitive 
to WBI in vivo since the cells will not be able to repair its damage caused by radiation and 
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will undergo mitotic catastrophe. Thus, testing simvastatin plus WBI in SUM149 TN-IBC 
brain metastasis model may be a useful next step to help us understand if the findings are 
similar to findings in MDA-IBC3. 
A second HER2+ model would also add to the robustness of our findings. However, 
using our tail vein brain metastasis model, none of the other HER2+ IBC cell lines (SUM190 
and KPL4) successfully metastasize to the brain (unpublished data from our lab). 
An additional limitation is the immunocompromised state inherent to all 
xenograft models. The SCID-Beige model lacks both T and B cells. Radiation causes death 
of cancer cells and which in turn releases antigens, some of which are presented by 
dendritic cells (neo-antigens) to T cells for immune attack against cancer. Since our mouse 
model lack T cells, it may not mimic what happens in humans. Since we used a human IBC 
cell line, an immunocompromised mouse was required to prevent cell rejection. There 
are no syngeneic mouse models derived from IBC cells. 
Another limitation is the lack of positive control for radiation sensitization. 
Unfortunately, there is no proven whole brain radiosensitizer approved in the clinic for 
IBC brain metastasis which could be used as a positive control. Further, our efforts to 
assess the efficacy of simvastatin treatment given in the water in the conditions chosen 
for reduction of cholesterol were limited. Several approaches were undertaken. MSI was 
used to explicitly assess cholesterol. While descriptive images demonstrate less signal in 
simvastatin treated versus control no radiation groups, further work is needed to 
determine if this represents real signal and to power this to analyze significance. 
Nevertheless, this highlighted a potentially interesting and unexpected finding. The no 
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radiation brains have lower baseline MSI cholesterol signal than the whole brain 
irradiated samples. This warrants more rigorous exploration but may imply that in vivo, 
whole brain radiation may paradoxically upregulate cholesterol beyond that perturbed 
by simvastatin.  
As mentioned in the discussion and introduction before, either simvastatin (25) or 
PCI (unpublished) were effective by themselves to prevent IBC brain metastasis using our 
tail vein injection mouse model. Simvastatin and low dose PCI could be tested for its 
efficacy to prevent the incidence of brain metastasis in our pre-clinical IBC mouse model. 
If the results are promising, it has a high potential to be translated into the clinic where 
patients with breast cancer, who are at high risk for developing brain metastasis, can be 
given very low dose WBRT along with simvastatin thus reducing the toxicity caused by 
high dose WBRT to the brain. 
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